Rx drugs

According to the results of the year 2013 total sales of the top five best selling Rx drugs amounted to RUR 1,639.1 million, which corresponds to 44.0% of sales in the Rx drugs segment and 31.1%[1] of the Company's total sales.

According to the results of the year 2013 the top five best selling Rx drugs are:

  • Geptor (Ademetionine; ATC[2] «Digestive tract and metabolism»); sales increased by 20.6% as compared to the same period of the previous year; 14.9% of sales in the Rx drugs segment;
  • Cerepro (Choline Alfoscerate; ATC «Medications for the treatment of the nervous system diseases»); sales in the segment made 9.6%;
  • Tautax (Docetaxel; ATC «Antineoplastic and immunomodulating agents»); sales in the segment made 9.5%;
  • Irunine (Itraconazole; ATC «Antimicrobials for systematic use»); sales in the segment made 5.0%;
  • Parclitaxel-LENS (Parclitaxel; ATC «Antineoplastic and immunomodulating agents»); sales in the segment made 4.9%;
OTC drugs

OTC drugs segment is characterized by the high degree of consolidation. It means that the top five best selling medicines make 98.4% of sales.

  • Xilen (Xylometazoline; ATC «Medications for the treatment of respiratory system»); sales in the OTC drugs segment made 49.1%;
  • Slabilen (Sodium picosulfate; ATC «Alimentary tract and metabolism»); sales in the OTC drugs segment made 30.0%;
  • Motilak (Domperidone; ATC «Alimentary tract and metabolism»); sales in the OTC drugs segment made 15.3%;
  • Vitasharm and Vitatress (ATC «Vitamins»); sales in the OTC drugs segment made 3.2%;
  • Ginkgo biloba (Ginkgo biloba; ATC «Medications for the treatment of urogenital organs»); sales in the OTC drugs segment made 0.8%.
Traditional drugs segment

According to the results of 2013 the top five best selling traditional drugs are:

  • Vero-Dexamethasone (Dexamethasone; ATC «Hormonal drugs for systematic use»); sales in the traditional drugs segment made 39.7%;
  • Pyridoxine (ATC «Alimentary tract and metabolism»); sales in the segment made 27.6%;
  • Vero-Ciprofloxacin (Ciprofloxacin; ATC «Antimicrobials for systematic use»); sales in the segment made 12.4%;
  • Vero-Loperamide (Loperamide; ATC «Alimentary tract and metabolism»); sales in the segment made 12.0%;
  • Vero-Flukonazole (Fluconazole; ATC «Antimicrobials for systematic use»); sales in the segment made 4.4%;
Non-pharamaceutical products

According to the results of 2013 the top five best selling non-pharamaceutical products are:

  • Conventional antimicrobial adhesive bandages; 36.8% of sales in the segment;
  • Conventional reel adhesive bandages; 23.2% of sales in the segment;
  • Therapeutic patches - pepper plasters; 20.0% of sales in the segment;
  • Therapeutic patches - corn plasters; 15.4% of sales in the segment;
  • Comida (ATC "Nutritional therapy"); 2.4% of sales in the segment.
NEW DRUGS PRODUCTION AND SALES

During 2013 Veropharm initiated production and sales of new forms and dosages of the following drugs:

  • Anfibra (Enoxaparin sodium; ATC «Medications affecting hematogenesis and blood»);
  • Salbutamol (Salbutamol; ATC «Medications for the treatment of respiratory system»);
  • ACP (Escitolapram, ATC «Medications for the treatment of the nervous system diseases»);
  • Gistamel (Imatinib; ATC «Antineoplastic and immunomodulating agents»);
  • Vero-Ifosfamide (Ifosfamide; ATC «Antineoplastic and immunomodulating agents»);
  • Iriten (Irinotecan; ATC «Antineoplastic and immunomodulating agents»);
  • Mielastra (Filgrastim; ATC «Antineoplastic and immunomodulating agents»);
  • Bereta (Rabeprazole; ATC «Alimentary tract and metabolism»);
  • Motilak (Domperidone; ATC «Alimentary tract and metabolism»);
  • GeptorDaily (Ademetionine; ATC «Alimentary tract and metabolism»);
  • Timolol-LENS (Timolol; ATC "Medications for the sense organs treatment");
  • Vero-Stavudine (Stavudine; ATC «Antimicrobials for systematic use»);
  • Betaver (Betahistine; ATC "Medications for the treatment of nervous system");
  • Poludan (Polyadenilic acid + Polyuridilic acid; ATC "Medications for the sense organs treatment").

During 2013 Veropharm has initiated the sales of new forms of the following non-pharmaceutical products:

  • «Sensex» (Condoms; ATC «Medical items»);
  • Sticking plaster "Uniplast" (ATC «Medical items»);
  • Sticking plaster "Veroplast" (ATC «Medical items»).
NEW DRUGS REGISTRATION

In the year 2013 Veropharm received registration for the following 3 drugs:

  • ACP (Escitolapram, ATC «Medications for the treatment of the nervous system diseases»);
  • Gistamel (Imatinib; ATC « Antineoplastic and immunomodulating agents»);
  • Bixicam (Meloxicam; ATC "Medications for the treatment of the muscularskeletal system diseases").

In the year 2013 the following two substances were included in the State register of medicines and medical products:

  • Carboplatin produced by LLC "LENS-Pharm";
  • Tropisetron hydrochloride produced by QUILU Pharmaceutical Co. Ltd., China.

In the year 2013 the following non-pharmaceutical products were registered:

  • Detoksiver - dietary supplement;
  • 14 dietary products for weight control "Nutrico Diet®";
  • 9 perfume and cosmetic products.
NEW DRUGS REGISTRATION IN CIS COUNTRIES

In the year 2013 the following 3 drugs produced by LLC "LENS-Pharm" were registered in CIS countries:

  • Geptaver, lyophilizate for preparation of a solution for intravenous and intramuscular injection 400 mg in the Republic of Belarus (ATC «Alimentary tract and metabolism»);
  • CONTRILENS, lyophilizate for preparation of a solution for intravenous injection 10 000 antitrypsin in the Republic of Uzbekistan (proteolysis inhibitor);
  • Vero-Methotrexat, solution for injections 5 mg/ml, 10 mg/ml in the Republic of Uzbekistan (ATC "Oncology drug, antimetabolite").

[1]   % - percent of finished goods sales
[2]  ATC - anatomico-therapeutico-chemical group

Press-release

distributed by